Slide 1: Insulet Corporation Q1 2023 Earnings
Insulet Corporation Q1 2023 Earnings May 4, 2023 Christian D Podder Since 2020
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statemen
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents consta
Slide 4: Recent Highlights
Recent Highlights Highlights • Record quarterly U.S. and global Omnipod new customer starts for any first quarter • FDA clearance of Omnipod GOTM, a first-of-its-kind basal-only insulin Pod • On track to commercially launch Omnipod 5 in the United Kingdom mid-year and in Germany in the fall • Advanc
Slide 5: Strategic Highlights
Strategic Highlights Grant H Morgan M Alecia B Podder Since 2022 Podder Since 2009 Podder Since 2017 Expand Access & Awareness International Innovation & Clinical • Record quarterly U.S. and Total Omnipod new • Building cloud-based infrastructure to deliver the • Received FDA clearance for Omnipod G
Slide 6: Financial Performance
Financial Performance Total Revenue & Growth Rates1 U.S. Omnipod Revenue and Growth Rates1 Adjusted Gross Profit and Margin2 Int'l Omnipod Revenue and Growth Rates1 Adjusted Operating Income & Margin2 Total Omnipod Revenue & Growth Rates1 1. Growth rates are on a year-over-year basis and for 2020 th
Slide 7: Key Commercial Metrics- Q1 2023
Key Commercial Metrics- Q1 2023 ~70% 15-20% >85% U.S. New Customer Starts By Product of U.S. New of U.S. New of U.S. Volume Starts were MDI Starts were through Type 2 Pharmacy ~10% Stable Global Global Attrition1 Utilization Note: All commercial metrics are directional estimates derived from various
Slide 8: Product Development Status- Q1 2023
Product Development Status- Q1 2023 Legend Innovation Pipeline U.S. Commercialized Regulatory Product International Submission Development Classic Omnipod Omnipod DASH Omnipod 5 Full market release CE Mark September 2022; w/ G6 August 2022 On track for mid-2023 launch Omnipod GO Data products 510(k)
Slide 9: Guidance Highlights - 2023
Guidance Highlights - 2023 FY 2023 Q2 2023 FY 2023 Adjusted FY 2023 Adjusted Revenue Growth1 Revenue Growth1 Gross Margin2 Operating Margin2 High-Single 18% to 22% 27% to 30% 65% to 66% Digits U.S. Omnipod U.S. Omnipod Expect 2H'23 to be closer to Expect 2H'23 to be higher than 27% to 31% 37% to 40%
Slide 10: Revenue Guidance Reconciliation
Revenue Guidance Reconciliation FY 2023 Q2 2023 Revenue Growth Currency Revenue Growth Currency GAAP Impact Constant Currency GAAP Impact Constant Currency U.S. Omnipod 27% to 31% —% 27% to 31% 37% to 40% —% 37% to 40% International Omnipod 8% to 12% 2% 6% to 10% 14% to 17% 1% 13% to 16% Total Omnip
Slide 11: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP % of Measures % of % of % of % of FY2020 Revenue FY2021 Revenue FY2022 Revenue Q1 2022 Revenue Q1 2023 Revenue Total Revenue GAAP Growth Rate 22.5% 21.5% 18.8% 17.1% 21.2% Less: Currency Impact 0.6% 1.8% (3.7)% (2.2)% (2.1)% Constant Currency 21.9% 19.7% 22.5% 19.3% 23.3%